Molecular Partners's DARPin molecules encouraging in preclinical action vs COVID-19

• Molecular Partners (OTCPK:MLLCF +3.9%) has announced supportive preclinical data from in vivo assessments of its DARPin candidates targeting SARS-CoV-2.
• In the five-day experiment, all animals treated with DARPin molecules (MP0420 or MP0423) recovered and survived, while 83% of animals in the placebo group had to be euthanized due to severe disease progression.
• "The clinical efficacy observed in both prophylactic and post exposure settings, especially in the context of the severity of disease displayed by our novel COVID-19 model, holds promise for this class of virus-neutralizing inhibitors in later line settings," said Jakob Trimpert, lead investigator of the study.
• First-in-human studies for MP0420 are anticipated to begin in November, and clinical studies for the second antiviral candidate, MP0423, are expected to initiate in H1 2021.
• https://seekingalpha.com/news/3620204-molecular-partnerss-darpin-molecules-show-encouraging-preclinical-action-against-covidminus